Sandoz to build US$90M Biosimilar Development Centre in Slovenia by 2026

Jul 20, 2023

Sandoz announced that it will invest US$90M to build a Biosimilar Technical Development Centre in Ljubljana, Slovenia by 2026.  The site will house an end-to-end drug substance and product development centre, becoming a ‘key location’ for Sandoz’s biosimilar product development.

This news comes only a few months after Sandoz signed an MOU to build a USD$400M biologics facility in Lendava, Slovenia in March 2023.

Print Page Mail Article